KCNQ3
ENSG00000184156
Target class
Ion channel
Chromosome
8
Approved drugs
5
Clinical candidates (approved and in development)
8
- Approved drugs
- 5
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Other names
- Kv7.3
- Target name
- KCNQ3
- Gene name
- Potassium voltage-gated channel subfamily Q member 3
- Gene symbol
- KCNQ3
- Previous gene symbols
- EBN2
- Protein name
- Potassium voltage-gated channel subfamily KQT member 3 (KQT-like 3) (Potassium channel subunit alpha KvLQT3) (Voltage-gated potassium channel subunit Kv7.3)
- Gene biotype
- Protein coding
- Gene family
- Potassium voltage-gated channels
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 19
- Highest tissue expression
- 22.58
- Tissue specificity (Gini)
- 0.717
- Tissue specificity (tau)
- 0.885
- KEGG gene identifiers
- hsa:3786
- Protein interaction confidence
- 0.847138
- Protein interaction partners
- 29
- R-HSA-1296072
- R-HSA-445095
- End position
- 132481095
- Start position
- 132120861
- Chromosome
- 8
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 10788442
- Tissue specificity (tau)
- 0.885029
- Expression inequality (Gini)
- 0.717216
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 22.58
- Brain - Cortex
- 18.16
- Brain - Anterior cingulate cortex (BA24)
- 17.45
- Brain - Nucleus accumbens (basal ganglia)
- 15.73
- Brain - Caudate (basal ganglia)
- 11.58
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)22.58
- Brain - Cortex18.16
- Brain - Anterior cingulate cortex (BA24)17.45
- Brain - Nucleus accumbens (basal ganglia)15.73
- Brain - Caudate (basal ganglia)11.58
- Brain - Amygdala10.55
- Brain - Putamen (basal ganglia)8.58
- Brain - Hypothalamus8.56
- Brain - Hippocampus7.79
- Brain - Substantia nigra4.38
- Pituitary3.45
- Lung2.74
- Brain - Spinal cord (cervical c-1)2.54
- Cells - Cultured fibroblasts2.27
- Brain - Cerebellum2.16
- Adipose - Subcutaneous1.89
- Artery - Coronary1.34
- Brain - Cerebellar Hemisphere1.24
- Breast - Mammary Tissue1.05
- Kidney - Medulla0.96
- Nerve - Tibial0.95
- Spleen0.9
- Adipose - Visceral (Omentum)0.87
- Thyroid0.82
- Artery - Tibial0.74
And 29 more, listed on the interactive page.
- GO:0007268
- GO:0071805
- GO:0005886
- GO:0008076
- GO:0005249
- GO:0005515
- GO:0005516
- GO:0022843
Related records
Trials (548)
- 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
- 4-aminopyridine for Skin Wound Healing
- 4-Aminopyridine in Episodic Ataxia Type 2
- 4-Aminopyridine to Treat Skin Burns
- 4-aminopyridine Treatment for Nerve Injury
- 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
- 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
- 4-AP Peripheral Nerve Crossover Trial
- 4AP for Carpal Tunnel Syndrome (CTS)
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A Comparative Study of Oral Gabapentin, Oral Alprazolam and Intravenous Dexmedetomidine on Perioperative Anxiety and Pain During Posterior Segment Eye Surgery Under Peribulbar Block : a Randomized, Double-blind Study.
- A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
- A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures
- A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain
- A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
- A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
- A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
- A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
Drugs (15)
- Amifampridine Voltage-gated potassium channel blocker
- Amifampridine phosphate Voltage-gated potassium channel blocker
- Azetukalner
- Dalfampridine Voltage-gated potassium channel blocker
- Ezogabine KCNQ (Kv7) potassium channel opener
- Flindokalner Voltage-gated potassium channel KCNQ3/KCNQ4 activator
- Gabapentin
- Guanidine Voltage-gated potassium channel blocker
- Guanidine hydrochloride Voltage-gated potassium channel blocker
- JNJ-37822681
- Nerispirdine Voltage-gated potassium channel blocker
- Tedisamil Voltage-gated potassium channel blocker
- Tedisamil sesquifumarate Voltage-gated potassium channel blocker
- Tetrylammonium
- Tetrylammonium bromide